Crux Biolabs
- Company typePrivate
- Founded2011
- HeadquartersBayswater, Australia
- Headcount11–50
- GTM typeB2B
- OfferingServices
Crux Biolabs firmographics
Firmographics- Name
- Crux Biolabs
- Legal name
- Crux Biolabs Pty Ltd
- Website
- https://cruxbiolabs.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Crux Biolabs industry classification
Industry- NAICS
- Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD)
- akta.pro secondary industries
- Clinical Research & Trial Central Laboratories (HLAFAMAL), Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB), Clinical CROs (Phase I–IV) (HLAGAAAA)
Keywords
Where Crux Biolabs is headquartered
LocationHeadquarters
- HQ city
- Bayswater
- HQ country
- Australia
- HQ region
- Oceania
Offices1 record
Markets served
Crux Biolabs business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Contract Research Services (CRO): Fee-for-service bioanalytical testing for clinical and pre-clinical trials. Clients engage via Master Services Agreements with project-specific work orders. Revenue generated through assay development, validation, and sample testing services for pharmaceutical and biotech sponsors.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Crux Biolabs product offering
Product offeringCore offering
Crux Biolabs is a contract research organization (CRO) that provides fee-for-service bioanalytical and immunology laboratory testing for pharmaceutical, biotechnology, and academic sponsors. Its core offering is a comprehensive suite of pre-clinical and clinical trial immunology services including ELISA, Luminex multiplex, MesoScale Discovery (MSD) assays, conventional and spectral flow cytometry, PBMC processing, in vitro cell culture, ELISpot/FluoroSpot, nucleic acid extraction, and anti-drug antibody (ADA) immunogenicity testing, delivered from a NATA ISO 17025 and GCLP accredited PC2 facility in Bayswater, Victoria.
Product overview
Crux Biolabs is a leading Australian bioanalytical Contract Research Organization (CRO) providing a comprehensive suite of laboratory testing services for pre-clinical and clinical trials. The service portfolio centers on immunology and biomarker analysis, comprising multiple distinct service lines including ELISA, Luminex multiplex, and MesoScale Discovery (MSD) platforms for biomarker detection; conventional and spectral flow cytometry for cell analysis; PBMC processing and in vitro cell culture for cellular immunology; ELISpot/FluoroSpot for T-cell analysis; and Anti-Drug Antibody (ADA) assay services for immunogenicity testing. The company offers both custom assay development and a library of pre-validated panels. Services are delivered from NATA ISO 17025 accredited PC2 laboratories in Melbourne and Sydney, with global reach through a spectral flow cytometry alliance with KCAS Bio.
Differentiator
Problem solved
Functional benefit
Quantifiable outcome
- Clinical trial data accepted by FDA, EMA, and compatible with global regulatory submissions
- +2 more outcomes
Companies that use Crux Biolabs
Customer profileNamed customers5 records
Segments3 records
Crux Biolabs technology and API
TechnologyAPI detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
Crux Biolabs partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core, flagship and minor.
- AccelagencoreAustralian CRO partner providing clinical research organization services including full program oversight, site selection, and recruitment. Part of joint delegation presenting 'Advantage Australia' at Swiss Biotech Day.
- Veritus ResearchcoreAustralian Phase I clinical facility partner offering 42-bed Phase I clinical facility and access to healthy volunteer and patient recruitment networks. Part of joint delegation presenting 'Advantage Australia' at Swiss Biotech Day.
- RDI PartnerscoreStrategic advisory partner providing guidance on access to Australia's R&D tax incentives and financial planning for international sponsors. Part of joint delegation presenting 'Advantage Australia' at Swiss Biotech Day.
- KCAS BioflagshipGlobal Spectral Flow Cytometry Alliance enabling harmonized spectral flow cytometry across US, Europe, and Australia using Cytek Aurora platform. KCAS Bio selected Crux Biolabs as partner to provide CRO services in Australia, with centralized data analysis for consistent clinical trial results globally.
- Global Lab Network PartnerscoreEstablished partnership with global laboratory network for coordinated clinical trial support services across multiple geographic regions.
- Local Accredited Laboratory Partners (Oncology and Virology)minorPartnerships with local accredited labs in oncology and virology to provide comprehensive service offerings for clinical trials requiring specialized testing.
Scale indicators4 records
Recent moves11 records
Expansion highlights6 records
Crux Biolabs competitors and assessment
Company assessmentBroad incumbents
- Labcorp Drug Development (Fortrea): Large global central and bioanalytical laboratory with extensive flow cytometry, biomarker and immunogenicity service lines. Competes for the same pharma and biotech sponsor work Crux targets, particularly in multi-region trials.
- PPD / Thermo Fisher Scientific Clinical Research: Global CRO and central laboratory services arm of Thermo Fisher offering bioanalytical, immunogenicity and biomarker testing at scale. A broad incumbent that competes for large clinical trial lab work.
- IQVIA Laboratories: Global central laboratory and bioanalytical services arm of IQVIA offering biomarker, immunogenicity, flow cytometry and PK/PD testing. Competes for large multi-site clinical trial bioanalytical contracts that Crux also targets.
- Charles River Laboratories: Major global CRO with a large bioanalytical and safety assessment business including immunogenicity, biomarkers and flow cytometry. Comparable in assay category but with vastly broader scale and geographic footprint.
- SGS Health Science: Global testing and contract research provider with bioanalytical, immunogenicity and biomarker services for pharma. Overlaps Crux's immunology and biomarker assay portfolio across global clinical trials.
- Eurofins Scientific: Global testing services conglomerate with extensive bioanalytical, immunogenicity and central laboratory capabilities serving pharma clients. A broad incumbent with overlapping offerings across biomarker, PK/PD and immunoassay testing.
Emerging players
- Bionova Scientific: US-based analytical and bioanalytical CRO providing cell-based assays, ELISA, MSD and flow cytometry services to biotech clients. An emerging specialist with meaningful overlap in assay menu but smaller scale and primarily US footprint.
Regional players
- Avance Clinical: Australian full-service CRO focused on early-phase clinical trials, leveraging Australia's CTN scheme. It is a regional peer addressing the same 'Advantage Australia' go-to-market that Crux is built around, though it is more clinical-operations oriented.
Direct peers
- 360biolabs: Australian specialty bioanalytical and immunology CRO providing flow cytometry, biomarker, PK/PD and vaccine testing services to pharma and biotech sponsors. A direct domestic competitor serving overlapping customer segments with comparable assay menus.
- KCAS Bio: US-headquartered bioanalytical and immunogenicity CRO offering PK/PD, ADA, biomarkers, and flow cytometry services. KCAS Bio is Crux Biolabs' global spectral flow alliance partner and the most directly comparable specialist immunology/bioanalytical peer.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Crux Biolabs social profiles
Digital presenceCrux Biolabs compliance and trust
Trust signalCompliance4 records
Crux Biolabs financial estimates
Financial estimateRevenue estimate
Valuation estimate
Crux Biolabs leadership team
Management profileNumber of profiles
Crux Biolabs funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Crux Biolabs M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Crux Biolabs
What does Crux Biolabs do?
Crux Biolabs is a contract research organization (CRO) that provides fee-for-service bioanalytical and immunology laboratory testing for pharmaceutical, biotechnology, and academic sponsors. Its core offering is a comprehensive suite of pre-clinical and clinical trial immunology services including ELISA, Luminex multiplex, MesoScale Discovery (MSD) assays, conventional and spectral flow cytometry, PBMC processing, in vitro cell culture, ELISpot/FluoroSpot, nucleic acid extraction, and anti-drug antibody (ADA) immunogenicity testing, delivered from a NATA ISO 17025 and GCLP accredited PC2 facility in Bayswater, Victoria.
Is Crux Biolabs a public or private company?
Crux Biolabs is a private company. It is currently operating.
When was Crux Biolabs founded?
Crux Biolabs was founded in 2011. It employs 11 to 50 people.
Where is Crux Biolabs based?
Crux Biolabs is headquartered in Bayswater, Australia, in the Oceania region.
How does Crux Biolabs make money?
One revenue line is on record: contract Research Services (CRO).
Who are Crux Biolabs's main competitors?
Broad incumbents on record are Labcorp Drug Development (Fortrea), PPD / Thermo Fisher Scientific Clinical Research, IQVIA Laboratories, Charles River Laboratories, SGS Health Science and Eurofins Scientific. Bionova Scientific is listed as an emerging player. Avance Clinical is listed as a regional player. Direct peers are 360biolabs and KCAS Bio.
Does Crux Biolabs have an API?
No public API is recorded for Crux Biolabs.
What industry is Crux Biolabs in?
Its primary akta.pro industry code is HLAGAAAD, Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity), with a secondary code of HLAFAMAL, Clinical Research & Trial Central Laboratories. Its NAICS code is 621511 and its SIC code is 8071.